US Patent

US11491176 — Methods for treating or preventing ophthalmological conditions

Method of Use · Assigned to Iveric Bio Inc · Expires 2034-07-11 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating or preventing ophthalmological conditions by administering certain drugs, including Antagonist A or an anti-C5 agent, to a subject in need of treatment.

USPTO Abstract

The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3673 avacincaptad-pegol-sodium

Patent Metadata

Patent number
US11491176
Jurisdiction
US
Classification
Method of Use
Expires
2034-07-11
Drug substance claim
No
Drug product claim
No
Assignee
Iveric Bio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.